Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires 292,850 Shares of Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 292,850 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were purchased at an average price of $4.93 per share, with a total value of $1,443,750.50. Following the completion of the acquisition, the insider owned 686,116 shares of the company’s stock, valued at $3,382,551.88. This represents a 74.47% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Friday, July 31st, Adar1 Capital Management, Llc bought 36,303 shares of NextCure stock. The shares were acquired at an average price of $4.94 per share, with a total value of $179,336.82.
• On Wednesday, July 29th, Adar1 Capital Management, Llc acquired 3,410 shares of NextCure stock. The stock was bought at an average price of $5.00 per share, with a total value of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc purchased 6,400 shares of NextCure stock. The stock was bought at an average price of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The shares were purchased at an average price of $5.00 per share, for a total transaction of $38,990.00.

NextCure Stock Up 6.3%

Shares of NXTC stock traded up $0.26 on Monday, reaching $4.40. The stock had a trading volume of 405,433 shares, compared to its average volume of 931,919. The firm’s 50-day moving average is $3.49 and its two-hundred day moving average is $8.65. The firm has a market capitalization of $15.89 million, a price-to-earnings ratio of -0.26 and a beta of 1.42. NextCure, Inc. has a 12 month low of $1.55 and a 12 month high of $15.74.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, sell-side analysts forecast that NextCure, Inc. will post -7.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NextCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cable Car Capital LP grew its position in shares of NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after buying an additional 88,040 shares during the last quarter. Geode Capital Management LLC boosted its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the last quarter. Exome Asset Management LLC acquired a new stake in NextCure during the 4th quarter valued at approximately $2,341,000. Finally, AWM Investment Company Inc. acquired a new stake in NextCure during the 4th quarter valued at approximately $1,665,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Wall Street Zen lowered shares of NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of NextCure in a report on Wednesday, July 15th. Finally, Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $19.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.